NRX Pharmaceuticals, Inc.

Thank you for standing by. This is the conference operator. Welcome to the NRX Pharmaceuticals third quarter 2023 earnings conference call. As a reminder, all participants are in listen only mode and the conference is being recorded. After the presentation, there will be an opportunity to ask questions. To join the question queue, you may press star then one on your telephone keypad. Should you need assistance during the conference call, you may signal an operator by pressing star and zero. I would now like to turn the conference over to Matthew Duffy, Chief Business Officer. Please go ahead.

Thank you, Ashia, and welcome everyone.

Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under U.S. federal securities laws. These statements are subject to risks and uncertainties that could cause actual results to develop materially from historical precedent, experience, or present expectations. Additional information concerning factors that could cause actual results to differ from the statements made on this call is contained in our periodic reports filed with the SEC. The forward-looking statements made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements. Information presented on this call is contained in the press release issued yesterday and in the company's Form 10-Q that was filed earlier today. which may be accessed from the Investors page on the NRX Pharmaceutical Incorporated website. Joining me today on today's call are Stephen Willard, Chief Executive Officer, Dr. Jonathan Javitt, our Founder and Chief Scientist, and Richard Merito, Chief Financial Officer and Treasurer. Stephen and Jonathan will provide a summary of the company's progress, Rich will review the company's financial results, and then Stephen will review upcoming milestones before making closing comments. Following their prepared remarks, we will address investor questions.